• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Stoke Therapeutics Inc.

    11/14/24 9:00:12 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $STOK alert in real time by email
    SC 13G/A 1 p24-3206sc13ga.htm STOKE THERAPEUTICS, INC.
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*
     

    Stoke Therapeutics, Inc.

    (Name of Issuer)
     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)
     

    86150R107

    (CUSIP Number)
     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    x Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 86150R10713G/APage 2 of 7 Pages

     

    1

    NAME OF REPORTING PERSON

     

    Lynx1 Capital Management LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)¨

    (b)¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    5,187,191

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    5,187,191

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    5,187,191

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.9%

    12

    TYPE OF REPORTING PERSON

    PN

             

     

     

    CUSIP No. 86150R10713G/APage 3 of 7 Pages

     

     

    1

    NAME OF REPORTING PERSON

     

    Weston Nichols

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)¨

    (b)¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States of America

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    5,187,191

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    5,187,191

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    5,187,191

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.9%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

    CUSIP No. 86150R10713G/APage 4 of 7 Pages

     

     

    Item 1(a). Name of Issuer.
       
      Stoke Therapeutics, Inc. (the “Issuer”)

     

    Item 1(b). Address of Issuer’s Principal Executive Offices.
       
     

    45 Wiggins Ave.

    Bedford, MA 01730

     

    Item 2(a). Name of Person Filing.
       
      This statement is filed by:

     

      (i)

    Lynx1 Capital Management LP (the “Investment Manager”), a Delaware limited partnership, and the investment manager to Lynx1 Master Fund LP (the “Lynx1 Fund”) and a managed account, with respect to the shares of Common Stock (as defined in Item 2(d) below) directly held by the Lynx1 Fund and the managed account; and

     

      (ii) Mr. Weston Nichols (“Mr. Nichols”), the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager, with respect to the shares of Common Stock directly held by the Lynx1 Fund and the managed account.

     

      The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.”
       
      The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein.
       
       
    Item 2(b). Address of Principal Business Office.
       
     

    Lynx1 Capital Management LP

    151 Calle de San Francisco

    Suite 200, PMB 1237

    San Juan, PR 00901-1607

     

    Weston Nichols

    c/o Lynx1 Capital Management LP

    151 Calle de San Francisco

    Suite 200, PMB 1237

    San Juan, PR 00901-1607

       
    Item 2(c). Place of Organization.
       
     

    Investment Manager – Delaware

    Mr. Nichols – United States of America

     

    CUSIP No. 86150R10713G/APage 5 of 7 Pages


     

    Item 2(d). Title of Class of Securities.
       
      Common stock, $0.0001 par value per share (the “Common Stock”)

     

    Item 2(e). CUSIP Number.
       
      86150R107

     

    Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a:

     

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) ¨ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
      (f) ¨

    An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

      (g) o

    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

      (h) ¨

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);

     

      (i) ¨

    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution:_____________________

     

    CUSIP No. 86150R10713G/APage 6 of 7 Pages

     

     

    Item 4. Ownership.
       
      The information required by Items 4(a) – (c)  is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each  Reporting Person.
       
      The percentages set forth herein are calculated based upon 52,647,799 shares of Common Stock outstanding as of July 31, 2024, as reported in the Issuer’s Quarterly Report on 10-Q for the quarterly period ended June 30, 2024, filed with the Securities and Exchange Commission on August 7, 2024.

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      Not applicable.

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       
      See Item 2. The Lynx1 Fund has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of more than five percent of the outstanding Common Stock.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       
      Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.
       
      Not applicable.

     

    Item 9. Notice of Dissolution of Group.
       
      Not applicable.

     

    Item 10. Certification.
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. 86150R10713G/APage 7 of 7 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date:  November 14, 2024  
     

    Lynx1 capital management lp

    By: Lynx1 Capital Management GP LLC, its general partner

     

       
      By:  /s/ Weston Nichols
      Name:  Weston Nichols
      Title:    Sole Member
       
       
       
       
      /s/ Weston Nichols
      WESTON NICHOLS

     

     

    Get the next $STOK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $STOK

    DatePrice TargetRatingAnalyst
    12/20/2024$24.00Buy
    Chardan Capital Markets
    10/14/2024$18.00Outperform
    Leerink Partners
    3/26/2024Market Perform → Outperform
    TD Cowen
    11/20/2023Neutral
    JP Morgan
    7/25/2023Outperform → Market Perform
    TD Cowen
    5/1/2023$9.00 → $12.00Underperform → Neutral
    BofA Securities
    4/26/2023$24.00Buy
    Canaccord Genuity
    1/6/2023$22.00 → $9.00Buy → Underperform
    BofA Securities
    More analyst ratings

    $STOK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital Markets initiated coverage on Stoke Therapeutics with a new price target

      Chardan Capital Markets initiated coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $24.00

      12/20/24 7:51:37 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners resumed coverage on Stoke Therapeutics with a new price target

      Leerink Partners resumed coverage of Stoke Therapeutics with a rating of Outperform and set a new price target of $18.00

      10/14/24 7:42:47 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stoke Therapeutics upgraded by TD Cowen

      TD Cowen upgraded Stoke Therapeutics from Market Perform to Outperform

      3/26/24 8:09:24 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STOK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

      Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that Interim Chief Executive Officer Ian F. Smith will present at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 8:45 a.m. ET. A live webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke's website at https://investor.stoketherapeutics.com/. About Stoke The

      4/1/25 4:30:00 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

      – Phase 3 EMPEROR study of zorevunersen, a first-in-class potential disease-modifying medicine for Dravet syndrome, on track to initiate in 2Q 2025 – – As of December 31, 2024, the Company had $246.7 million in cash, cash equivalents, and marketable securities; together with the $165 million upfront and eligible proceeds from Biogen collaboration anticipated to fund operations to mid-2028 – Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syn

      3/18/25 7:00:00 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stoke Therapeutics Announces CEO Transition

      Edward M. Kaye, M.D., to Step Down as Chief Executive Officer Director Ian F. Smith Appointed Interim Chief Executive Officer Arthur Tzianabos Appointed Interim Executive Chairman of the Board Board of Directors Initiates Search for Permanent Chief Executive Officer Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today the Company announced that Edward M. Kaye, M.D., has decided to step down from his role as Chief Executive Offi

      3/18/25 6:58:00 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STOK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF MEDICAL OFFICER Ticho Barry sold $266,953 worth of shares (26,631 units at $10.02), decreasing direct ownership by 44% to 33,998 units (SEC Form 4)

      4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)

      5/5/25 4:08:50 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Levin Arthur A converted options into 1,210 shares (SEC Form 4)

      4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)

      4/2/25 4:03:15 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Interim CEO Smith Ian F

      4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)

      3/20/25 6:19:44 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STOK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Stoke Therapeutics Inc.

      SC 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)

      11/14/24 9:00:58 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Stoke Therapeutics Inc.

      SC 13G - Stoke Therapeutics, Inc. (0001623526) (Subject)

      11/14/24 4:24:49 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Stoke Therapeutics Inc.

      SC 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)

      11/14/24 9:00:12 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STOK
    SEC Filings

    See more
    • SEC Form 144 filed by Stoke Therapeutics Inc.

      144 - Stoke Therapeutics, Inc. (0001623526) (Subject)

      5/1/25 4:45:41 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Stoke Therapeutics Inc.

      DEFA14A - Stoke Therapeutics, Inc. (0001623526) (Filer)

      4/22/25 4:06:17 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Stoke Therapeutics Inc.

      DEF 14A - Stoke Therapeutics, Inc. (0001623526) (Filer)

      4/22/25 4:05:27 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STOK
    Leadership Updates

    Live Leadership Updates

    See more
    • Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer

      – Mr. Olson brings two decades of successful corporate business development experience with an emphasis on rare diseases and RNA therapeutics – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced the appointment of Eric Olson as Chief Business Officer. Mr. Olson has two decades of experience in life sciences business development and strategy with a track record of success, completing numerous transactions to maximize value for company pipelines across a variety of therapeutic areas, including rare genetic diseases, neurology and ophthalmology. In his new role, Mr. Ol

      9/4/24 8:00:00 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer

      – Mr. Hoitt brings more than two decades of successful commercial experience with an emphasis on rare diseases – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Jason Hoitt as Chief Commercial Officer. Mr. Hoitt has more than 20 years of experience successfully planning and executing commercial strategies at leading biopharma companies. As Chief Commercial Officer and a member of Stoke's leadership team, Mr. Hoitt will be responsible for overseeing the Company's global commercial strategy for STK-001. Recently annou

      4/17/24 8:00:00 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stoke Therapeutics Appoints Ian Smith to its Board of Directors

      – Mr. Smith brings significant experience in the successful development and commercialization of medicines for rare genetic diseases – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Ian Smith to its Board of Directors effective September 19. "Ian brings more than two decades of significant executive management experience in the life sciences industry, with a strong track record of successfully building valuable biotech businesses," said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics. "His div

      9/20/23 4:30:00 PM ET
      $FHTX
      $SLDB
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $STOK
    Financials

    Live finance-specific insights

    See more
    • GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025

      Grew fourth quarter 2024 revenues1 to $95.3 million Expanded fourth quarter 2024 adjusted gross margins1,2 to 70% Generated fourth quarter 2024 adjusted net income2 of $16.8 million FY 2025 revenue guidance of $350M to $360M, exome/genome volume and revenue growth of at least 30% GeneDx to host conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the fourth quarter and full year of 2024. "The fourth quarter capped an outstanding year for GeneDx, as we work to end the diagnostic odyssey with earlier intervention using our industry-leading exome and gen

      2/18/25 6:00:00 AM ET
      $BIIB
      $PRAX
      $STOK
      $WGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Retail: Computer Software & Peripheral Equipment
    • Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

      – Alignment achieved with U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) and Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for EMPEROR – – One-year study of zorevunersen will evaluate reductions in major motor seizure frequency as well as improvements in behavior and cognition in children and adolescents ages 2 to <18 years old – – FDA Breakthrough Therapy designation positions zorevunersen on efficient development path; Company plans to start Phase 3 in mid-2025 – – Webcast and conference call for analysts and investors at 8:00AM Eastern Time today – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein

      1/7/25 7:00:00 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome

      Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that its management team will host a webcast and conference call for investors and analysts to discuss successful alignment with global regulatory agencies related to a Phase 3 study of zorevunersen as potentially the first disease-modifying medicine for the treatment of Dravet syndrome. The webcast will be conducted Tuesday, January 7, 2025 at 8:00am Eastern Time and can be accessed from the Investors & News section of Stoke's website at https://investor.stoketherapeutics.com/. Research analysts who plan to join th

      1/6/25 4:30:00 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care